A. Salvado

Allan H Friedman, James M Provenzale, R. McLendon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erythroid differentiation of clonal Rauscher erythroleukemia cells in response to erythropoietin or dimethyl sulfoxide.

A. Salvado, G. Smith, A. Sytkowski, 1980, Science.

Early effects of imatinib mesylate on the expression of insulin‐like growth factor binding protein‐3 and positron emission tomography in patients with gastrointestinal stromal tumor

K. Hunt, Wei Zhang, Limei Hu, 2006, Cancer.

Signature program: a platform of basket trials

D. Berry, S. Stein, F. Meric-Bernstam, 2018, Oncotarget.

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

R. McLendon, J. Provenzale, H. Friedman, 2007, Journal of Neuro-Oncology.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Abnormal responses of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor in human cyclic neutropenia.

D. Wright, A. Salvado, V. Larussa, 1989, The Journal of clinical investigation.

Resolution of pure red cell aplasia and lymphoma: Response to intravenous gammaglobulin and combination chemotherapy

S. Vukelja, A. Salvado, J. Krishnan, 1989, American journal of hematology.

Phase II open label trial of imatinib in polycythemia rubra vera

A. Salvado, C. Jones, T. Dickinson, 2005, International journal of hematology.

Inhibition of bone marrow myeloid precursor cell proliferation by chemotactic oligopeptides.

A. Salvado, D. Wright, P. Mora, 1982, Blood.

An analysis of the multilineage production of human hematopoietic progenitors in long-term bone marrow culture: evidence that reactive oxygen intermediates derived from mature phagocytic cells have a role in limiting progenitor cell self-renewal.

D. Wright, R. Meagher, A. Salvado, 1988, Blood.

The Signature Program: Bringing the Protocol to the Patient

S. Stein, C. Lebedinsky, A. Salvado, 2015, Clinical pharmacology and therapeutics.

Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM)

H. Friedman, D. Reardon, J. Rich, 2007 .

Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2004, Blood.

Molecular Responses in Newly Diagnosed Chronic Myelocytic Leukemia (CML) Patients Treated with 800 mg Imatinib Daily: An Update from the RIGHT Trial Study Group.

J. Radich, H. Kantarjian, K. McDougall, 2006 .

Treatment of polycythemia vera with imatinib mesylate.

R. Silver, J. Spivak, E. Feldman, 2012, Leukemia research.